Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance
Author:
Affiliation:
1. Faculty of Medicine, Tehran University of Medical Science (TUMS), Tehran, Iran
2. Department of Immunology, School of Medicine, Iran University of Medical Science (IUMS), Tehran, Iran
Publisher
Informa UK Limited
Subject
Pharmacology,Toxicology,General Medicine,Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/08923973.2021.1925294
Reference102 articles.
1. Pawar AY. Combating devastating Covid-19 by drug repurposing. Elsevier, 2020.
2. Sardu C, Onofrio ND, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–1415.
3. Pal R, Sanjay KB. Covid-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metab Syndr. 2020:14(4):513–517.
4. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes the role of reparatory mechanisms. Diabetes Care. 2011;34(Suppl.):S285–S290.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Metformin Restrains the Proliferation of CD4+ T Lymphocytes by Inducing Cell Cycle Arrest in Normo- and Hyperglycemic Conditions;Biomolecules;2024-07-14
2. Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes;Diabetes, Obesity and Metabolism;2024-05-14
3. Anti-Inflammatory Potential of the Anti-Diabetic Drug Metformin in the Prevention of Inflammatory Complications and Infectious Diseases Including COVID-19: A Narrative Review;International Journal of Molecular Sciences;2024-05-10
4. Sharing is Caring: Drug Repurposing among Leading Diseases;Recent Advances in Biotechnology;2024-03-12
5. Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps;BJC Reports;2023-12-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3